Regulatory decisions made by the Food and Drug Administration (FDA) often serve as important catalysts for pharmaceutical stocks. In the following video, health-care analyst Max Macaluso discusses three upcoming FDA decisions -- on drugs developed by pharma giant Merck (MRK 0.37%), GlaxoSmithKline (GSK 0.49%), and needle-free injection pioneer Antares Pharma (ATRS) -- and why investors need to keep a close watch on the outcomes of these decisions.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The Food and Drug Administration will decide on drugs developed by Merck, Antares Pharmaceuticals, and GlaxoSmithKline in the coming months.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.